Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
Zepbound and Wegovy are the two leading FDA-approved weight loss injectable medications in 2026 — and they’re genuinely different drugs with different mechanisms, different average weight loss outcomes, and different cost structures. Here’s the full comparison to help you decide.
Quick Comparison
| Factor | Zepbound (Tirzepatide) | Wegovy (Semaglutide) |
|---|---|---|
| Manufacturer | Eli Lilly | Novo Nordisk |
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist only |
| FDA approval | Chronic weight management (2023) | Chronic weight management (2021) |
| Injection frequency | Once weekly | Once weekly |
| Average weight loss (max dose) | ~22.5% body weight | ~14.9% body weight |
| % losing 20%+ body weight | 63% of participants | 32% of participants |
| Retail price (no insurance) | ~$499–1,060/mo | ~$1,349/mo |
| LillyDirect / direct program | Yes (~$349–499/mo) | NovoCare savings (varies) |
| Compounded version | Available (503A pharmacies) | Widely available ($99–250/mo) |
| Cardiovascular outcomes trial | SURMOUNT-MMO (ongoing) | SELECT (20% MACE reduction shown) |
Why Zepbound Produces More Weight Loss
Tirzepatide hits two receptors — GLP-1 and GIP (glucose-dependent insulinotropic peptide). The dual action appears to provide stronger appetite suppression and metabolic effects than GLP-1 alone. This is why the weight loss numbers are so much higher:
- Zepbound at 15mg: Average 22.5% body weight loss; 63% of participants lost 20%+
- Wegovy at 2.4mg: Average 14.9% body weight loss; 32% of participants lost 20%+
At 200 lbs, that difference is 30 lbs vs 45 lbs of expected weight loss. Not trivial.
Side Effect Comparison
Both medications have similar GI side effect profiles — nausea, diarrhea, constipation, vomiting — because they share the GLP-1 mechanism. Tirzepatide’s additional GIP action doesn’t appear to meaningfully worsen side effects in most studies. However:
- Both are associated with the same key risks: pancreatitis, gallbladder disease, thyroid C-cell tumor concern
- Both are contraindicated in personal/family history of MTC or MEN2
- Side effects peak during dose escalation and typically improve significantly at maintenance doses
- Individual tolerability varies — some people who have poor tolerance on one may do better on the other
Cost Comparison: The Real Numbers
This is where it gets interesting — and where Zepbound has an advantage despite being the more effective drug:
| Access Route | Zepbound Cost | Wegovy Cost |
|---|---|---|
| Retail (no insurance) | ~$499–1,060/mo | ~$1,349/mo |
| With insurance (covered) | $0–50/mo | $0–50/mo |
| Manufacturer direct program | ~$349–499/mo (LillyDirect) | No equivalent program |
| Savings card (commercially insured) | ~$25/mo (Zepbound card) | Varies |
| Compounded (telehealth) | ~$150–350/mo | ~$99–250/mo |
Notably, Wegovy’s retail price is actually higher than Zepbound’s, despite being less effective — a result of launch timing and pricing strategy. If you’re paying out of pocket, compounded semaglutide (Wegovy equivalent) remains the most affordable option at ~$99–250/month, while compounded tirzepatide (Zepbound equivalent) runs ~$150–350/month.
Which Should You Choose?
| Your Situation | Better Choice |
|---|---|
| Want maximum weight loss | Zepbound / tirzepatide |
| Budget-conscious (out of pocket) | Compounded semaglutide (~$99/mo) |
| Tried semaglutide, didn’t respond well | Zepbound / tirzepatide |
| Have type 2 diabetes | Mounjaro (tirzepatide) — stronger blood sugar control |
| Insurance covers one but not the other | Whichever is covered |
| New to GLP-1 therapy, unsure | Start with semaglutide (lower cost, more data) |
🏆 Top GLP-1 Programs for 2026
MetaboLabs — Affordable compounded semaglutide from ~$99/mo. Great starting point.
TrimLabs — Offers tirzepatide options with physician oversight and health coaching.
Compare all GLP-1 providers → | Tirzepatide cost breakdown →
Real-World Considerations: Availability and Switching Between Medications
While clinical data helps compare Zepbound and Wegovy on paper, real-world factors like drug availability and switching logistics significantly impact your treatment experience. Both medications have experienced intermittent supply shortages since launch, so checking current availability with your pharmacy before committing to a prescription is advisable. If you need to switch between these two drugs, your healthcare provider will typically develop a cross-titration plan to minimize side effects during the transition. Insurance prior authorization requirements differ between Zepbound and Wegovy, with some plans requiring documented failure on one medication before approving the other. Patients who respond well to one GLP-1 receptor agonist generally respond positively to others, though individual results vary. Keep a detailed log of your weight loss progress to help your provider make data-driven decisions about any medication changes.
Sources & References
- U.S. Food and Drug Administration (FDA) – Drug Approvals and Databases
- National Institutes of Health (NIH) – PubMed Medical Literature
- American Diabetes Association – Medication & Therapies
- Novo Nordisk – Clinical Research Data
- Eli Lilly – Medical Information
This content is regularly reviewed and updated to reflect the latest medical research and FDA guidance.